[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Asahi Kaisei Crp ADR (AHKSY)

Asahi Kaisei Crp ADR (AHKSY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Asahi Kasei Microdevices Begins Mass Production of Camera‑less Modules for Detection of Falls, Vital Signs, Posture, and Position

Mass production of the AK5816AIM mmWave radar module Detection of falls, vital signs, posture, and position without cameras or wearables ...

AHKSY : 21.4900 (-6.57%)
Asahi Kasei Adds New Slitting Facility for SUNFORT™ to Meet Growing Demand for Advanced Semiconductor Packaging

Asahi Kasei, a diversified global company, constructed a new slitting facility for SUNFORT™ dry film photoresist (DFR) at its manufacturing site in Tainan, Taiwan, on July 3. Commercial operations are...

AHKSY : 21.4900 (-6.57%)
Asahi Kasei’s Novel Forward Osmosis–Membrane Distillation System Installed at Peptistar's API Manufacturing Facility for Reduced Pharmaceutical Manufacturing Time

Japanese pharmaceutical contract development and manufacturing organization (CDMO) Peptistar has integrated Asahi Kasei’s novel forward osmosis–membrane distillation...

AHKSY : 21.4900 (-6.57%)
EAS Batteries Starts Sales of Ultra-High-Power Cell Using Asahi Kasei’s Novel Electrolyte Acetolyte™

German battery manufacturer EAS Batteries has commercialized its ultra-high-power lithium-ion LFP cell, initially launched in March 2026. The cell incorporates Asahi Kasei’s novel acetonitrile-containing...

AHKSY : 21.4900 (-6.57%)
Asahi Kasei Life Science Acquires License for Novel Antibody-Drug Conjugate Technology from The Noguchi Institute – A Major Milestone for More Efficient and Safer Cancer Treatments

Asahi Kasei Life Science has acquired the license rights for a novel antibody-drug conjugate (ADC) technology from The Noguchi Institute. This modality enables precise control over the drug-to-antibody...

AHKSY : 21.4900 (-6.57%)
Asahi Kasei Develops Novel Photosensitive Polyimide Film for Advanced Panel-Level Semiconductor Packaging

Panel-level packaging has gained momentum in the semiconductor industry as manufacturers pursue higher efficiency and improved yield that can support next-generation packaging processes. In response to...

AHKSY : 21.4900 (-6.57%)
Asahi Kasei Microdevices Debuts AK491x Premium Audio Op Amps at HIGH END Vienna 2026

Asahi Kasei Microdevices (AKM), a subsidiary of Asahi Kasei, has unveiled the AK491x series of premium audio operational amplifiers (op amps). These new devices mark a significant expansion of AKM’s...

AHKSY : 21.4900 (-6.57%)
Asahi Kasei Optimizes Material Portfolio Through Supply Realignment by FY2030

Asahi Kasei, a diversified global company, has announced plans to streamline operations at its Mizushima Works by fiscal 2030. This press release features multimedia. View the...

AHKSY : 21.4900 (-6.57%)
Asahi Kasei Completes Acquisition of Aicuris to Advance Its Global Pharmaceutical Strategy

Aicuris’s three antiviral assets complement Asahi Kasei’s therapy portfolio Aicuris revenue expected to reach $500 million by...

AHKSY : 21.4900 (-6.57%)
Asahi Kasei Announces Initiation of Phase I Clinical Trial for Novel Peptide Candidate Targeting Autoimmune Diseases

Asahi Kasei, a diversified global company, today announced the initiation of a Phase I clinical trial for AK1940, a novel peptide-based investigational compound developed to address significant unmet medical...

AHKSY : 21.4900 (-6.57%)

Barchart Exclusives

Palantir Is Set to Deliver Strong Q2. Analysts See 60% Upside Potential for PLTR Stock.
Palantir's revenue growth continues to accelerate, profit margins are expanding, and demand for Palantir's AI platform remains robust. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.